This report, by the Taskforce Horizon Scanning of the Beneluxa Initiative, describes the current situation of Alzheimer’s disease and provides an overview of new pharmaceutical developments regarding…
The Beneluxa Initiative aims to ensure sustainable access
to innovative medicine at affordable cost for our patients.
Pharmaceutical Developments on Alzheimer’s Disease
Ministers of Health acknowledge the importance of a HTA on Covid Therapeutics
On December 6th, Ministers of Health and representatives of the Beneluxa countries met to discuss the Beneluxa Initiative. Subjects of this exchange on political level were the current state of…
The information on the Joint HTA assessment of ZYNTEGLO has been updated
ZYNTEGLO betibeglogene autotemcel (shorter name: beti-cel) was jointly assessed as a Beneluxa pilot, which led to a successful publication of this joint effort in July 2021. The pharmacotherapeutic…